Mr Gemignani brings to Coronado 25 years of accounting, planning and finance experience that includes employment at a broad spectrum of life science businesses including emerging biotech, big pharma and accounting and consultancy.
Additionally, Mr Gemignani was most recently executive vice president and chief financial officer at Gentium, a publicly traded, late-stage biotechnology company focused on the development and manufacturing of drugs to treat and prevent vascular diseases related to cancer.
Prior to joining Gentium, Mr Gemignani held senior financial positions at Novartis, Prudential Financial, Wyeth and Arthur Andersen.
Tesi, president and CEO of Coronado Biosciences, said: “Gary brings operational leadership and finance and management expertise to the company’s executive management team. His range of experience working with both biotech and life science companies will contribute to the success of Coronado.”
Mr Gemignani, said: “Given Coronado Biosciences’ technology, I believe there is value to be unlocked and look forward to working with the management and board to accomplish the company’s goals.”